<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Date of Report (date of earliest event reported):
<B>February 15, 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Fuse Science, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Nevada</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(State or other jurisdiction of incorporation)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; border-bottom: black 1.5pt solid; font-weight: bold; text-align: center">&nbsp;000-22991</TD>
    <TD STYLE="width: 4%; padding-bottom: 1.3pt">&nbsp;</TD>
    <TD STYLE="width: 48%; border-bottom: black 1.5pt solid; text-align: center">&nbsp; <B>87-0460247</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(IRS Employer Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>6135 N.W. 167<SUP>th</SUP> Street, Suite
E-21, Miami Lakes, Florida 33180</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;(Address of principal executive offices
and zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: black 1.5pt solid; font-weight: bold; text-align: center">(305) 503-3873</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(Registrant&rsquo;s telephone number including area code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: black 1.5pt solid; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">Former Name or Former Address (If Changed Since Last Report)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 4%; font-family: Wingdings; text-align: justify"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 4%; font-family: Wingdings; text-align: justify"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 4%; font-family: Wingdings; text-align: justify"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 4%; font-family: Wingdings; text-align: justify"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17&nbsp;CFR&nbsp;240.13e&#45;4(c))</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As used in this Current Report on Form 8-K
and unless otherwise indicated, the terms the &ldquo;<B>Company</B>,&rdquo; &ldquo;<B>Fuse,</B>&rdquo; &ldquo;<B>we</B>,&rdquo;
&ldquo;<B>us</B>,&rdquo; and &ldquo;<B>our</B>&rdquo; refer to Fuse Science, Inc. and its subsidiaries, unless the context requires
otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 5.02.</B></TD><TD STYLE="text-align: justify"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Directors.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Effective February 15,
2012, Jeanne Hebert<B> </B>joined the Company full time as its Vice President of Marketing and Clinical Research, after serving
on our advisory board since April 2011. Ms.&nbsp;Hebert, 43, brings more than 20 years sales, marketing and research experience
in the pharmaceutical and medical device industries, having worked for leading global manufacturers Bristol-Myers Squibb, Bayer
Pharmaceutical, Merck &amp; Co. and Integral Orthopedics, Inc.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During her tenure at Merck,
from November 1999 to May 2005, she provided direction on science-based content to support Merck's strategic objectives in the
Respiratory and Ophthalmology franchises.&nbsp;&nbsp;As a member of their scientific advisory board, she created the scientific
platform for the Respiratory Health Science organization.&nbsp;&nbsp;In addition to crafting compelling sales messages from the
supporting science, her role involved identifying and engaging thought leaders (leading researchers and academics), in peer-level,
scientific discussions to convert them into advocates for Merck's products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">From May 2005 to June 2008,
Ms. Hebert worked for and was vice president of marketing and member of the senior executive team of Integral Orthopedics.&nbsp;&nbsp;In
this capacity, she advanced product innovation through development and commercialization phases, including work with suppliers
on product design and advanced medical prototyping.&nbsp; Ms. Hebert led aggressive corporate intellectual property protection
via case management, better designs and web protection strategies to strengthen the company's defenses against competition.&nbsp;&nbsp;In
her executive capacity, she also designed and initiated Integral Orthopedics' internal and external clinical studies and provided
oversight on testing of new products in the company's internal research facility, leading to favorable outcomes and the launch
of several new products. From June 2008 to June 2010, she was Vice President of Marketing for DBI Inc., a medical product innovation
company focused in the field of podiatry and from June 2010 until joining Fuse, Ms.&nbsp;Hebert worked as a technical analyst and
consultant for Boeing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Ms. Hebert holds a B.S.
degree in biology from Washington State University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Ms. Hebert is not party
to an employment agreement with the Company at present. She will receive an initial base salary of $100,000, subject to adjustment
by our board of directors in its discretion. In addition, she will be entitled to receive such bonuses as may be awarded by the
board of directors in its discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Upon her joining the Company
as an executive officer, Ms. Hebert was granted options to purchase 1,000,000 shares of our common stock at an exercise price of
$0.331 per share under our 2011 Incentive Stock Plan. Of these options, 600,000 vest upon grant, with the balance vesting in equal
quarterly 50,000 share installments over a two year period, contingent on her continued employment. The options expire five years
form the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, Ms. Hebert
has previously been granted options to purchase 400,000 shares at a price of $0.39 per share, when she joined our advisory board
in April 2011. These options originally provided for vesting in two equal installments on the first and second anniversaries of
grant, contingent on her continued service on our advisory board. As Ms. Hebert has stepped down from our advisory board to join
the Company on a full-time basis, the options have been amended to provide that their vesting is contingent upon her continued
employment with Fuse. The options expire five years from the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">FUSE SCIENCE, INC.</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 40%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.3pt">Date:&nbsp;&nbsp;February 17, 2012</TD>
    <TD STYLE="padding-bottom: 1.3pt">By:</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">/s/&nbsp;Brian Tuffin</TD>
    <TD STYLE="padding-bottom: 1.3pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Name:&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">Brian Tuffin</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Its:&nbsp;&nbsp;</TD>
    <TD>Chief Executive Officer</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v303136_8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 17711}]
{"company-data": {"conformed-name": "Fuse Science, Inc.", "cik": "0000842722", "assigned-sic": "6799", "irs-number": "870460247", "state-of-incorporation": "NV", "fiscal-year-end": "0930"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-22991", "film-number": "12622241"}, "business-address": {"street1": "6135 NW 167TH STREET", "street2": "#E21", "city": "MIAMI", "state": "FL", "zip": "33015", "phone": "305-503-3873"}, "mail-address": {"street1": "6135 NW 167TH STREET", "street2": "#E21", "city": "MIAMI", "state": "FL", "zip": "33015"}, "former-company": [{"former-conformed-name": "Double Eagle Holdings, Ltd.", "date-changed": "20070123"}, {"former-conformed-name": "ONSPAN NETWORKING INC", "date-changed": "20010214"}, {"former-conformed-name": "NETWORK SYSTEMS INTERNATIONAL INC", "date-changed": "19960516"}]}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (date of earliest event reported):
February 15, 2012
Fuse Science, Inc.
(Exact name of registrant as specified in charter)
Nevada
(State or other jurisdiction of incorporation)
000-22991
87-0460247
(Commission File Number)
(IRS Employer Identification No.)
6135 N.W. 167
th
Street, Suite
E-21, Miami Lakes, Florida 33180
(Address of principal executive offices
and zip code)
(305) 503-3873
(Registrant's telephone number including area code)
Former Name or Former Address (If Changed Since Last Report)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
£
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
£
Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)
£
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
£
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
As used in this Current Report on Form 8-K
and unless otherwise indicated, the terms the "
Company
," "
Fuse,
" "
we
,"
"
us
," and "
our
" refer to Fuse Science, Inc. and its subsidiaries, unless the context requires
otherwise.
Item 5.02.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Directors.
Effective February 15,
2012, Jeanne Hebert
joined the Company full time as its Vice President of Marketing and Clinical Research, after serving
on our advisory board since April 2011. Ms. Hebert, 43, brings more than 20 years sales, marketing and research experience
in the pharmaceutical and medical device industries, having worked for leading global manufacturers Bristol-Myers Squibb, Bayer
Pharmaceutical, Merck & Co. and Integral Orthopedics, Inc.
During her tenure at Merck,
from November 1999 to May 2005, she provided direction on science-based content to support Merck's strategic objectives in the
Respiratory and Ophthalmology franchises.  As a member of their scientific advisory board, she created the scientific
platform for the Respiratory Health Science organization.  In addition to crafting compelling sales messages from the
supporting science, her role involved identifying and engaging thought leaders (leading researchers and academics), in peer-level,
scientific discussions to convert them into advocates for Merck's products.
From May 2005 to June 2008,
Ms. Hebert worked for and was vice president of marketing and member of the senior executive team of Integral Orthopedics.  In
this capacity, she advanced product innovation through development and commercialization phases, including work with suppliers
on product design and advanced medical prototyping.  Ms. Hebert led aggressive corporate intellectual property protection
via case management, better designs and web protection strategies to strengthen the company's defenses against competition.  In
her executive capacity, she also designed and initiated Integral Orthopedics' internal and external clinical studies and provided
oversight on testing of new products in the company's internal research facility, leading to favorable outcomes and the launch
of several new products. From June 2008 to June 2010, she was Vice President of Marketing for DBI Inc., a medical product innovation
company focused in the field of podiatry and from June 2010 until joining Fuse, Ms. Hebert worked as a technical analyst and
consultant for Boeing.
Ms. Hebert holds a B.S.
degree in biology from Washington State University.
Ms. Hebert is not party
to an employment agreement with the Company at present. She will receive an initial base salary of $100,000, subject to adjustment
by our board of directors in its discretion. In addition, she will be entitled to receive such bonuses as may be awarded by the
board of directors in its discretion.
Upon her joining the Company
as an executive officer, Ms. Hebert was granted options to purchase 1,000,000 shares of our common stock at an exercise price of
$0.331 per share under our 2011 Incentive Stock Plan. Of these options, 600,000 vest upon grant, with the balance vesting in equal
quarterly 50,000 share installments over a two year period, contingent on her continued employment. The options expire five years
form the date of grant.
2
In addition, Ms. Hebert
has previously been granted options to purchase 400,000 shares at a price of $0.39 per share, when she joined our advisory board
in April 2011. These options originally provided for vesting in two equal installments on the first and second anniversaries of
grant, contingent on her continued service on our advisory board. As Ms. Hebert has stepped down from our advisory board to join
the Company on a full-time basis, the options have been amended to provide that their vesting is contingent upon her continued
employment with Fuse. The options expire five years from the date of grant.
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
FUSE SCIENCE, INC.
Date:  February 17, 2012
By:
/s/ Brian Tuffin
Name:
Brian Tuffin
Its:
Chief Executive Officer
3